Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Dye

Internal Medicine Brookline, MA Medical Doctor

NPI 1225077217 CMS profile 55518

1199 Beacon St, Brookline, MA 02446

Open in the dashboard

General payments

$14,183

380 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Dye of Brookline, MA is reported in the CMS Open Payments database as having received $14,183 across 380 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $3,131 70
2022 General $2,622 71
2021 General $3,514 99
2020 General $1,327 68
2019 General $3,589 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Dye
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Dye were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Dye Internal Medicine median Middle half National median
2019 $3,589 $159 $48–$570 $163
2020 $1,327 $119 $33–$402 $114
2021 $3,514 $135 $37–$521 $132
2022 $2,622 $141 $42–$496 $149
2023 $3,131 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $4,368 109 payments
  2. Janssen Pharmaceuticals, Inc $1,528 32 payments
  3. Novo Nordisk Inc $1,319 22 payments
  4. Esperion Therapeutics, Inc. $1,268 53 payments
  5. Amgen Inc. $1,127 28 payments
  6. GlaxoSmithKline, LLC. $775 24 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $732 12 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $574 13 payments
  9. E.R. Squibb & Sons, L.L.C. $511 13 payments
  10. Pfizer Inc. $478 11 payments
  11. Other $1,504 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $13,956 370 payments
  2. Education $227 10 payments
Products named General payments · program years 2019–2023
  1. FARXIGA $3,178 83 payments
  2. XARELTO $1,398 31 payments
  3. NEXLETOL $1,246 52 payments
  4. Repatha $1,127 28 payments
  5. Ozempic $787 15 payments
  6. Kerendia $732 12 payments
  7. NEXLIZET $673 8 payments
  8. BREZTRI $628 9 payments
  9. JARDIANCE $574 13 payments
  10. TRELEGY ELLIPTA $551 16 payments
  11. Other $4,747 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Internal Medicine: 777

Drug cost

$318

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 16 $318

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

380 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record